Description
Indication & Scope
MYQORZO® Aficamten Tablets provides long-term treatment for adult patients diagnosed with obstructive hypertrophic cardiomyopathy (HCM) to reduce cardiac outflow tract obstruction and relieve exercise-limiting symptoms.
- Mechanism: Selective cardiac myosin ATPase inhibitor. It reversibly binds to cardiac β-myosin heavy chain, slows actin-myosin cross-bridge cycling, decreases left ventricular hypercontractility, reduces systolic anterior motion of mitral valve and relieves left ventricular outflow tract obstruction in HCM patients.
- Drug class: Oral small-molecule cardiac myosin inhibitor / Cardioprotective anti-hypertrophic cardiomyopathy agent.
- Clinical use: First-line long-term monotherapy for symptomatic obstructive HCM adults; improves exercise capacity, reduces chest pain, dyspnea and syncope risk, delays disease progression without surgical septal myectomy.
| Generic Name | Aficamten Tablets |
| Brand Name | MYQORZO |
| Ingredient | Aficamten |
| Dosage Form | Tablets |
| Package | 5mg*14 tablets*2 blisters/box |
| Conditions Treated | Obstructive hypertrophic cardiomyopathy (HCM) in adult symptomatic patients |
| Taboos | Severe hypersensitivity to aficamten or tablet excipients; patients with resting left ventricular ejection fraction (LVEF) <50%; pregnant and breastfeeding women; patients with uncorrected severe hypotension |
| Place of origin | 2100 Syntex Court, Mississauga, Ontario, L5N 7K9, Canada |
| Prescription type | Prescription-only |
| Storage Conditions | Store sealed blister packs at controlled room temperature 15°C to 30°C, sealed away from high humidity and direct sunlight |
| Manufacturer | Patheon Inc. |
| Registration Authority | National Medical Products Administration (NMPA), China |
| Approval number | HJ20250147 |
| Approval Date | Dec 16, 2025 |
| Shelf Life | 24 months |
How to use ?
Recommended Dose: Initial titration dose: 10 mg oral once daily; adjust incrementally to maintenance doses of 15 mg, 20 mg or 30 mg daily based on echocardiogram outflow tract gradient and symptom severity.
Time: Fixed single oral dose taken once daily, can be consumed with or without meals at consistent daily timing.
Instructions for use: Swallow whole tablet with clean water without crushing or splitting; conduct baseline echocardiogram before treatment, repeat cardiac ultrasound every 4 weeks during dose titration; hold dose if symptomatic hypotension occurs.
Interaction: Strong CYP3A4 inhibitors elevate systemic aficamten exposure and hypotension risk; strong CYP3A4 inducers drastically lower therapeutic plasma concentration, reducing anti-obstruction efficacy. Concurrent beta-blockers or calcium channel blockers amplify hypotension risk.
Side effects:
1. Common adverse reactions: mild fatigue, dizziness, orthostatic hypotension, diarrhea, palpitations.
2. Severe grade ≥3 risks: symptomatic severe hypotension, bradycardia, reduced left ventricular ejection fraction.
Important Notice
This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indicatiaon, and regional regulatory requirements.
Packaging & Shipping
Packaging
Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.
Shipping Methods
Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.
Export Support
Certificate of Analysis
GMP Certificate
Commercial Invoice
Packing List & CPP
Cold Chain Logistics
Customs Documentation
Scientific and regulatory sources
FAQ
What core cardiac protein target does Aficamten Tablets act on to treat obstructive HCM?
It selectively inhibits the ATPase activity of cardiac β-myosin heavy chain to weaken excessive myocardial contraction.
What mandatory cardiac test must clinicians perform before initiating Aficamten Tablets and during dose titration cycles?
Serial transthoracic echocardiograms to measure left ventricular outflow tract pressure gradients and LVEF.
Which two standard HCM medications amplify the hypotension risk when co-administered with Aficamten Tablets?
Beta-adrenergic blockers and non-dihydropyridine calcium channel blockers.
What key clinical symptom improvement serves as the primary therapeutic endpoint of Aficamten Tablets?
Reduction of exercise-induced dyspnea, chest pain and syncope by relieving left ventricular outflow tract mechanical obstruction.
MYQORZO® | Aficamten Tablets | HCM | DengYueRX
INN: Aficamten Tablets
Indications: Obstructive hypertrophic cardiomyopathy (HCM)
Dosage Form: Tablets
Strength: 5mg/tablet
